PATENT CLAIM ANALYSIS

Application Number: 16050102
Application Type: Utility
Filing Date: 2018-07
Publication Date: 2019-05
Patent Classification: ["514", "004800"]

Abstract:
The present invention relates to amylin analogues and to their use in the treatment or prevention of a variety of diseases, conditions or disorders, including obesity, excess food intake and associated metabolic diseases such as diabetes. The analogues have good physical and chemical stability, good solubility, and a long duration of action, and are well suited for use in the form of a liquid formulation.

Claim (Index 1):
An amylin analogue which is a compound having the formula:\n R 1 \u2014Z\u2014R 2  wherein R 1  is hydrogen, C 1-4  acyl, benzoyl or C 1-4  alkyl, or a half-life extending moiety M, wherein M is optionally linked to Z via a linker moiety L; R 2  is OH or NHR 3 , wherein R 3  is hydrogen or C 1-3 -alkyl; and Z is an amino acid sequence of formula I: (I) (SEQ\u2003ID\u2003NO:\u20033) X1-X2-X3-X4-X5-X6-X7-Ala-Thr-X10-Arg-Leu-Ala-X14- Phe-Leu-X17-Arg-X19-X20-Phe-Gly(Me)-Ala-Ile(Me)- X27-Ser-Ser-Thr-Glu-X32-Gly-Ser-X35-Thr-X37 wherein X1 is selected from the group consisting of Arg, Lys and Glu; X3 is selected from the group consisting of Gly, Gln and Pro; X4 is selected from the group consisting of Thr and Glu; X5 is selected from the group consisting of Ala and Leu; X6 is selected from the group consisting of Thr and Ser; X10 is selected from the group consisting of Glu and Gln; X14 is selected from the group consisting of Aad, His, Asp, Asn and Arg; X17 is selected from the group consisting of Gln, His and Thr; X19-X20 is selected from Ser-Ser, Thr-Thr, Ala-Thr, Ala-Ala, Gly-Thr, Gly-Gly and Ala-Asn or is absent; X27 is selected from the group consisting of Leu and Pro; X32 is selected from the group consisting of Val and Thr; X35 is selected from the group consisting of Asn and Ser; X37 is selected from the group consisting of Hyp and Pro; and X2 and X7 are amino acid residues whose side chains together form a lactam bridge; or a pharmaceutically acceptable salt thereof.

Metadata:
- Claim Count in Document: 13.0
- Percentile: 95.0
- Lexical Diversity: 1.4898
- Patent Class: 514.0
- Transitional Phrase Type: closed
- Component Type: 1
- Foreign Priority: True
- Related Applications: ['15698743', '14398260', '11278014', '14800627', '15442229']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8108238908134879
- 35 USC 102 Novelty (BERT): 0.7446334062690589
- Combined Prediction Score: 0.804204842359045
- Mean Citation Score: 487.11570200000006
- Max Citation Score: 847.1067
- Similarity Product: 832.8759248903813

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test